相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26
Bogdan Mitran et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label
Sarah Lindbo et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role
Sophia Spatz et al.
JOURNAL OF UROLOGY (2018)
Theranostic Perspectives in Prostate Cancer with the Gastrin Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results
Berthold A. Nock et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging
Sara Sheikhbahaei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26
Bogdan Mitran et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2017)
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
Louise Emmett et al.
JOURNAL OF MEDICAL RADIATION SCIENCES (2017)
Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26
Bogdan Mitran et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
Kristell L. S. Chatalic et al.
THERANOSTICS (2016)
The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26
Zohreh Varasteh et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with 18F-4-Fluorobenzaldehyde
Daniel Rosik et al.
BIOCONJUGATE CHEMISTRY (2014)
To Serve and Protect: Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting
Berthold A. Nock et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin
Zohreh Varasteh et al.
MOLECULES (2014)
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
X. Yuan et al.
ONCOGENE (2014)
The evolution of prostate cancer therapy: targeting the androgen receptor
Jeanny B. Aragon-Ching
FRONTIERS IN ONCOLOGY (2014)
Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging
Zohreh Varasteh et al.
BIOCONJUGATE CHEMISTRY (2013)
Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin
Rebecca A. Dumont et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
In Vitro and In Vivo Evaluation of a 18F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
Zohreh Varasteh et al.
PLOS ONE (2013)
PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues
Simone Daepp et al.
EJNMMI RESEARCH (2012)
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
Damian Wild et al.
CANCER RESEARCH (2011)
Bombesin Antagonist-Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors
Keelara Abiraj et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog
Jean Claude Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides
Rosalba Mansi et al.
CLINICAL CANCER RESEARCH (2009)
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules
Vladimir Tolmachev et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
177Lu-AMBA Biodistribution, Radiotherapeutic Efficacy, Imaging, and Autoradiography in Prostate Cancer Models with Low GRP-R Expression
Mary Ellen Maddalena et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation
Eftychia Koumarianou et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
Expression of the Gastrin-Releasing Peptide Receptor, the Prostate Stem Cell Antigen and the Prostate-Specific Membrane Antigen in Lymph Node and Bone Metastases of Prostate Cancer
Hildo J. K. Ananias et al.
PROSTATE (2009)
Diversity of biology in castrate resistant prostate cancer
Josef Fox et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Influence of the Molecular Charge on the Biodistribution of Bombesin Analogues Labeled with the [99mTc(CO)3]-Core
Elisa Garcia Garayoa et al.
BIOCONJUGATE CHEMISTRY (2008)
Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-ZHER2:342-pep2:: Implications for development of labeled tracers
Helena Wallberg et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2008)
Bombesin receptor antagonists may be preferable to agonists for tumor targeting
Renzo Cescato et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States
R. T. Jensen et al.
PHARMACOLOGICAL REVIEWS (2008)
99mTc-maEEE-ZHER2:342, an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors
Thuy Tran et al.
BIOCONJUGATE CHEMISTRY (2007)
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule
Torun Engfeldt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
68Ga-Labeled bombesin studies in patients with gastrointestinal stromal tumors:: Comparison with 18F-FDG
Antonia Dimitrakopoulou-Strauss et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-Bombesin(1-14)
Grainne B. Biddlecombe et al.
BIOCONJUGATE CHEMISTRY (2007)
Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases
Asa Liljegren Sundberg et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Potent Bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc:: A preclinical study
BA Nock et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors
HW Zhang et al.
CANCER RESEARCH (2004)
Peptide receptors as molecular targets for cancer diagnosis and therapy
JC Reubi
ENDOCRINE REVIEWS (2003)
[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging
B Nock et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent
R La Bella et al.
BIOCONJUGATE CHEMISTRY (2002)
Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study
C Van de Wiele et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
分享论文
